undamentalytics Newsletter
Sign in

Mirum Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Mirum Pharmaceuticals, Inc. had total assets of $843m, total liabilities of $528m and shareholders' equity of $315m. It held $297m in cash against $310m of debt: net debt of $13.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents1423128286223297331
Receivables03246878123145
Inventory02622222526
Total current assets236167190388393550636
Total assets2412953536476718431,045
Accounts payable3997151023
Total current liabilities18436587127206223
Long-term debt——0306308310750
Total debt000306308310750
Total liabilities691742113984455281,055
Shareholders' equity172120142249226315−10
Net debt (negative = net cash)−142−31−28208613419
Shares outstanding30m31m37m47m48m52m65m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: MIRM vs TARSARWR vs MIRMHCM vs MIRMMIRM vs NRIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mirum Pharmaceuticals, Inc.